We found that phase-I VTs were unaffected, but we observed lower arrhythmogenesis in rats pre-treated with GH during phase-II (Figure 2), resulting in lower arrhythmic and total mortality 24 h post-MI. This evidence concerns the gene GH1 and myocardial infarction.